Insulin activation of lipogenesis in isolated mammary acini from lactating rats fed on a high-fat diet. Evidence that acetyl-CoA carboxylase is a site of action.
Feeding lactating rats on high-fat cheese crackers in addition to laboratory chow increased the dietary intake of fat from 2 to 20% of the total weight of food eaten and decreased mammary-gland lipogenesis in vivo by approx. 50%. This lipogenic inhibition was also observed in isolated mammary acini, where it was accompanied by decreased glucose uptake. These inhibitions were completely reversed by incubation with insulin. Insulin had no effect on the rate of glucose transport into acini, nor on pyruvate dehydrogenase activity as estimated by the accumulation of pyruvate and lactate, suggesting that these are not the sites of lipogenic inhibition. Insulin stimulated the incorporation of [1-14C]acetate into lipid in acini from high-fat-fed rats. In the presence of alpha-cyanohydroxycinnamate, a potent inhibitor of mitochondrial pyruvate transport, and with glucose as the sole substrate, neither [1-14C]glucose incorporation into lipid nor glucose uptake were stimulated by insulin. Insulin did stimulate the incorporation of [1-14C]acetate into lipid in the presence of alpha-cyanohydroxycinnamate, and this was accompanied by an increase in glucose uptake by the acini. This indicated that increased glucose uptake was secondary to the stimulation of lipogenesis by insulin, which therefore must occur via activation of a step in the pathway distal to mitochondrial pyruvate transport. Insulin stimulated acetyl-CoA carboxylase activity measured in crude extracts of acini from high-fat-fed rats, restoring it to values close to those of chow-fed controls. The effects of insulin on acetyl-CoA carboxylase activity and lipogenesis were not antagonized by adrenaline or dibutyryl cyclic AMP.
D000085:Acetates / Q000378:metabolism; D019342:Acetic Acid; D000103:Acetyl-CoA Carboxylase / Q000378:metabolism*; D000818:Animals; D003373:Coumaric Acids / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology; D004041:Dietary Fats / Q000008:administration & dosage*; D004789:Enzyme Activation / Q000187:drug effects; D004837:Epinephrine / Q000494:pharmacology; D005227:Fatty Acids / Q000096:biosynthesis*; D005260:Female; D005947:Glucose / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology*; D007774:Lactation / Q000378:metabolism*; D008025:Ligases / Q000378:metabolism*; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D011247:Pregnancy; D011773:Pyruvates / Q000378:metabolism; D019289:Pyruvic Acid; D051381:Rats; D011919:Rats, Inbred Strains
D000085:Acetates; D003373:Coumaric Acids; D004041:Dietary Fats; D005227:Fatty Acids; D007328:Insulin; D011773:Pyruvates; C007175:alpha-cyano-4-hydroxycinnamate; D019289:Pyruvic Acid; D000242:Cyclic AMP; D008025:Ligases; D000103:Acetyl-CoA Carboxylase; D005947:Glucose; D019342:Acetic Acid; D004837:Epinephrine